ArticleFrontiers in public health2026
Reliability and validity of the Turkish translation of the MOS-HIV health survey in people living with HIV.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Health-related quality of life (HRQoL) is a key patient-centered outcome in HIV care, particularly in the current treatment era in which virological control is increasingly achievable but residual physical, mental, and social burden may persist. However, the clinical applicability of HIV-specific HRQoL instruments in Turkish-speaking people living with HIV (PLWH) remains insufficiently established. We aimed to characterize HRQoL in a multicenter Turkish sample of PLWH and to evaluate whether the Turkish version of the Medical Outcomes Study HIV Health Survey (MOS-HIV) provides reliable and valid scores for use in this population. Methods: In this multicenter cross-sectional study, PLWH receiving care at five tertiary training and research hospitals in Istanbul completed the Turkish MOS-HIV. Cognitive debriefing was performed in 20 participants, and 244 were included in the main analysis. Domain and summary scores were calculated according to the user's manual. Internal consistency was assessed in all 244 participants and test-retest reliability in a subsample of 105 after a median of 15 days. Structural validity was examined using domain-level confirmatory factor analysis and known-groups comparisons were conducted according to comorbidity status, CD4 category, history of AIDS-defining illness, and number of tablets in the treatment regimen. Results: Participants had a median age of 37 years and a median CD4 count of 701 cells/mm Conclusion: The Turkish MOS-HIV showed acceptable reliability and structural validity in a young, predominantly male, virologically suppressed population in urban tertiary care, and distinguished HRQoL differences by comorbidity, CD4 status, and history of AIDS-defining illness but not by tablet burden. Evaluation in women, older PLWH and more clinically heterogeneous populations is needed before broader use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.